City

Banjul (1)

Pittsburgh (1)

Condition

Human Papillomavirus Vaccine (2)

Quadrivalent HPV Vaccine (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Sign in for free

Phase

n/a (1)

phase 3 (1)

Sponsor

London School of Hygiene and Tropical Medicine (1)

University of Pittsburgh (1)

Collaborator

Merck Sharp & Dohme LLC (2)

Public Health England (1)

University of Cambridge (1)

Intervention

9-valent human papillomavirus vaccine (gardasil 9) - 1 dose (1)

9-valent human papillomavirus vaccine (gardasil 9) - 2 doses (1)

9-valent human papillomavirus vaccine (gardasil 9) - 3 doses (1)

quadrivalent human papillomavirus vaccine (1)

Study Documents

Intervention Type

biological (2)

Funder Type

Other (2)

Study Type

Interventional (2)

human papillomavirus vaccine

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Human Papillomavirus Vaccine Trial in Banjul (9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses, 9-valent human

Active, not recruiting

Human Papillomavirus Vaccine

9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
+2 more

Banjul, Outside U.S. And Canada, Gambia

Ed Clarke

Mar 15, 2022

Quadrivalent HPV Vaccine, Human Papillomavirus Vaccine Trial in Pittsburgh (quadrivalent human papillomavirus vaccine)

Completed

Has Results

Quadrivalent HPV Vaccine
Human Papillomavirus Vaccine

quadrivalent human papillomavirus vaccine

Pittsburgh, Pennsylvania

University of Pittsburgh

Feb 26, 2014